Background: Co-administration of antineoplastics with ART is challenging due to potential drug-drug interactions (DDIs). However, trials specifically assessing such DDIs are lacking. Our objective was to simulate DDIs between the antineoplastics erlotinib and gefitinib with key antiretroviral drugs and to predict dose adjustments using a physiologically based pharmacokinetic (PBPK) model.
Introduction
Widespread use of combination ART (cART) has been followed by a marked decrease in the mortality associated with HIV infection. 1 At the same time, however, the incidence of various comorbidities, including non-AIDS-defining cancers (NADCs), seems to have risen. [2] [3] [4] [5] [6] Several studies have shown that early and effective cART during chemotherapy increases survival rates, [7] [8] [9] [10] and initiation or maintenance of cART is currently recommended for HIV-infected patients with cancer. However, concomitant administration of cART and chemotherapy in clinical practice may be challenging due to the risk of overlapping toxicities and the potential for difficult-to-manage drug-drug interactions between antineoplastic and antiretroviral drugs. Many antineoplastics are substrates of metabolizing enzymes and drug transporters that can be inhibited or induced by antiretrovirals. This may lead to substantial changes in drug exposure, which, in turn, may result in increased toxic effects or in decreased efficacy of chemotherapy.
Since ritonavir is a potent inhibitor of both cytochrome P450 enzymes and drug transporters involved in the disposition of V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. numerous drugs, 11, 12 patients taking boosted-cART regimens are those at higher risk for drug interactions with antineoplastics. 9, 13, 14 On the other hand, some NNRTIs may induce cytochrome P450 enzymes 15 and could potentially reduce the exposure, and consequently the efficacy, of certain chemotherapy drugs. Despite the potential relevance of this issue, clinical data on drug-drug interactions between antineoplastic and antiretroviral drugs are very scant and ethical considerations limit the possibility of running formal clinical trials specifically aimed at addressing pharmacokinetic interactions between cART and chemotherapy.
Physiologically based pharmacokinetic (PBPK) modelling is a modelling approach that can be useful to predict drug-drug interactions in the absence of clinical data. This approach combines in vitro data (e.g. physicochemical characteristics, intrinsic clearance and permeability) with system data that describes the population of interest (e.g. demographic, anatomical and physiological characteristics) to simulate the pharmacokinetics of drugs. 16 This strategy is being widely used for drug development in different therapeutic areas and it has been considered by regulatory agencies as an alternative for exploring drug-drug interaction potential between a substrate drug and an interacting drug. 17 Erlotinib and gefitinib are two tyrosine kinase inhibitors (TKIs) with antiangiogenic activity which are used for the treatment of patients with several types of cancer, 18, 19 including those with non-small cell lung cancer, 20, 21 which is one of the most common NADCs observed in HIV-infected patients. 5, 13, [22] [23] [24] [25] Although erlotinib and gefitinib may be attractive treatment options due to their oral bioavailability and relatively favourable safety profile compared with cytotoxic drugs, their use is not exempt from possible adverse effects, which may be dose limiting. [26] [27] [28] Additionally, both erlotinib and gefitinib are substrates for different isoenzymes of the cytochrome P450 system, primarily CY3A4, 18, 19 which provides a rationale for significant drug interactions with antiretrovirals. Even so, clinical data on drug-drug interactions between these antineoplastics and antiretroviral agents are lacking.
The aim of this study was, therefore, to predict the magnitude of drug-drug interactions of erlotinib and gefitinib with a ritonavirboosted PI (darunavir/ritonavir) as well as with two NNRTIs (efavirenz and etravirine) simulating virtual clinical trials through PBPK modelling. The robustness of this approach was assessed by comparing the magnitude of simulated drug-drug interactions using two probe drugs for CYP3A4 (midazolam and maraviroc) with that observed in clinical trials. Finally, the validated model was used to simulate erlotinib and gefitinib dose adjustments to achieve therapeutic drug exposure when these agents are coadministered with antiretrovirals.
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Methods
A cohort of 50 healthy volunteers was generated. All organs and tissues were represented as individual compartments. Assumptions in the model were: (i) instant distribution of the drugs (well-stirred model); (ii) no drug absorption from the colon; and (iii) drug transport into tissues was blood flow limited. The PBPK model was designed using Simbiology (Matlab, version R2013b).
System parameters
Virtual healthy volunteers were generated using a population physiology model which provides a statistical description of the physiological and anatomical characteristics in the human population. 29 The physiology model reflects a population (0.5 proportion females) in the age range 20-50 years (mean age 36.5 6 13 years), with average height of 1.75 6 0.17 m and average weight of 76.3 6 14.6 kg. Individual values of age, height and body weight were used for the calculation of organ and tissue volumes through allometric equations. 29 Additionally, systemic blood circulation was simulated considering the cardiac output and regional blood flows as previously described. 29 Based on the study of Yu et al., 30 oral absorption was simulated by means of a compartmental absorption and transit model. Human effective permeability was evaluated using the apparent permeability in Caco-2 cell monolayer or based on the polar surface area (PSA) and hydrogen bond donor (HBD) values. 31 Intestinal and first-pass hepatic metabolism were evaluated considering the in vitro intrinsic clearance of each enzyme metabolizing the drug and the abundance of each enzyme in both intestinal and hepatic tissue. 32, 33 Hepatic clearance was simulated based on intrinsic clearance data according to Obach et al. 34 Enzyme inhibition in the gut and in the liver was described according to a mechanism-based inhibition model equation, using total concentrations of the inhibitor in the gut for gut metabolism and the free concentrations of the inhibitor in the liver for liver metabolism. Induction of enzyme expression in the gut and in the liver was expressed according to a maximum effect model equation, using total concentrations of the inducer in both cases.
The volume of distribution was simulated by calculating the plasma-totissue ratio for each organ, according to Poulin and Theil. 35 
Drug parameters
In vitro data describing physicochemical characteristics of erlotinib, gefitinib, ritonavir, darunavir, efavirenz and etravirine are summarized in Table S1 (available as Supplementary data at JAC Online). Similarly, data describing the metabolism of the drugs by different enzyme isoforms were available in the literature and intrinsic clearance values for these metabolic processes were included in the model as shown in Table S2 .
Simulation design
First, steady-state drug concentrations in plasma were simulated in a virtual population of 50 individuals receiving 150 mg of erlotinib once daily, 250 mg of gefitinib once daily, 800/100 mg of darunavir/ritonavir once daily, 600 mg of efavirenz once daily or 200 mg of etravirine twice daily. Second, to facilitate validation of the model, the inhibitory and inductive potential of darunavir/ritonavir, efavirenz and etravirine was evaluated with probe drugs for CYP3A4 (midazolam and maraviroc) and simulated interactions were compared with data from drug-drug interaction studies available in the literature. Finally, the validated model was used to simulate interactions between erlotinib and gefitinib and antiretroviral drugs, as well as plausible erlotinib and gefitininb dose adjustments to establish doses attaining comparable exposure to that in the absence of antiretrovirals.
Results
Simulated pharmacokinetics of erlotinib, gefitinib, darunavir, ritonavir, efavirenz and etravirine are shown in Table 1 . The pharmacokinetic parameters of each drug were comparable to clinical data.
Interactions with reference probes
Since ritonavir is a much more potent CYP3A4 inhibitor than darunavir, CYP3A4 inhibition by darunavir/ritonavir was described according to a competitive antagonistic model in which darunavir Molt o et al.
caused minimal additional CYP3A4 inhibition when ritonavir was present. 36 As shown in Figure 1 , the results of simulated trials of drug interactions between darunavir/ritonavir, efavirenz and etravirine with midazolam and maraviroc gave results comparable to those in the literature. The simulated interaction between ritonavir and midazolam (400 mg twice daily ritonavir plus a single oral dose of 2 mg midazolam) resulted in an increase in the midazolam area under the curve (AUC 0-inf ) by 10.4-fold, compared with the reported 8.14-fold in a clinical study. 37 Conversely, the simulated interaction between efavirenz (600 mg once daily) and maraviroc (100 mg twice daily) resulted in a 65% decrease in the AUC 0-12 of maraviroc, compared with 51% in the clinical study by Abel et al. 38 Finally, the interaction between etravirine and maraviroc has been evaluated by Kakuda et al. 39 who reported a 53% decrease in maraviroc AUC 0-12 when maraviroc (300 mg twice daily) was given with etravirine (200 mg twice daily), while the corresponding simulation resulted in a 49% decrease.
Interactions with antineoplastics
Darunavir/ritonavir caused a profound decrease in erlotinib firstpass metabolism and systemic clearance. This had a major effect on erlotinib pharmacokinetics, increasing AUC 0-24 and maximum plasma concentration (C max ) 6.8-and 5.4-fold, respectively. A dose reduction of erlotinib was simulated and a daily dose of 25 mg was predicted to overcome the effect of darunavir/ritonavir on erlotinib disposition (Table S3 and Similarly, darunavir/ritonavir increased gefitinib AUC 0-24 and C max 5.5-and 4.1-fold, respectively. It is noteworthy that gefitinib AUC 0-24 and C max were still increased by 2.79-and 2.05-fold, respectively, after halving the gefitinib dose to 125 mg once daily compared with standard dosing without darunavir/ritonavir (Table  S3 and Figure 2b ). Even so, gefitinib individual concentrations in this scenario were considered to be within the therapeutic range and this dose adjustment was considered appropriate. 28 Conversely to darunavir/ritonavir, efavirenz and etravirine induced the metabolism of erlotinib and gefitinib, with a subsequent decrease in drug exposure. Such a decrease was particularly marked in the case of efavirenz and it was not overcome even after doubling the dose of either erlotinib or gefitinib (Table S3 and Figure  2c and d) . In the case of etravirine, simulated dose increases of erlotinib and gefitinib showed that a daily dose of 200 mg erlotinib and 375 mg gefitinib was sufficient to provide pharmacokinetic parameters comparable to those obtained with standard dosing without etravirine (Table S3 and Figure 2e and f).
Discussion
The developed PBPK model described the pharmacokinetics of erlotinib, gefitinib, darunavir/ritonavir, efavirenz and etravirine, PBPK modelling to simulate drug-drug interactions JAC and their interactions. The clarification of the magnitude of drug-drug interaction between antiretroviral and antineoplastic drugs is relevant since the co-administration of both treatments is becoming relatively common in HIV-infected patients with cancer [7] [8] [9] [10] and changes in drug exposure may influence treatment outcomes. Virtual clinical trials were simulated and the extent of variation of the pharmacokinetic parameters of antineoplastics was investigated, identifying safer therapeutic options in relation to the risk of drug-drug interactions. This simulation approach can be viewed as a paradigmatic example demonstrating that PBPK modelling can be used to investigate relevant questions in difficult-to-explore clinical scenarios and to gain a better understanding of the molecular mechanisms underpinning drug disposition. Molt o et al.
Proper use of PBPK models to simulate drug-drug interactions requires deep knowledge of the physicochemical and metabolic properties of the drugs, including CYP inhibition and induction. Data describing the metabolism of drugs by different isoforms of the cytochrome P450 system were available from the literature. Erlotinib and gefitinib are metabolized primarily by CYP3A4 and to a lesser extent by other isoenzymes. 40 Ritonavir and darunavir are also primarily metabolized by the CYP3A isozyme family. 41, 42 Similarly, CYP2B6 and CYP3A4 are the major isozymes responsible for efavirenz metabolism, while etravirine is metabolized by CYP3A4 and CYP2C19. [43] [44] [45] According to FDA classification (moderate and strong inhibition: >2-fold but <5-fold increase in AUC, >5-fold increase in AUC, respectively; moderate and strong induction: 50%-80% decrease in AUC, >80% decrease in AUC, respectively), 17 the magnitude of the simulated drug-drug interactions with erlotinib or gefitinib was moderate to strong. These results are in agreement with previous preclinical studies, 46, 47 and can be explained because both erlotinib and gefitinib are mainly metabolized by CYP3A4, 40 which is strongly impacted by ritonavir and efavirenz as well as, to a lesser extent, by etravirine. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] 41, [43] [44] [45] Ritonavir is a strong inhibitor and a weak inducer of CYP3A4, while darunavir is a weak inhibitor and inducer of CYP3A4. 41, 42, 48 When considering drug interactions with darunavir/ritonavir, ritonavir was the main perpetrator and darunavir was considered to cause minimal additional CYP3A4 inhibition when ritonavir was present. This assumption was based on data by German et al. 36 who showed no additional CYP3A4 inhibition by ketoconazole to that caused by ritonavir. According to prescribing information, caution is advised when erlotinib needs to be co-administered with strong CYP3A4 inhibitors. 18 Such a recommendation is based on data showing an increase in erlotinib AUC of $80% when it was co-administered with ketoconazole. However, the increase in erlotinib concentrations caused by ritonavir in our study was much more pronounced than initially expected. This finding, together with the fact that erlotinib is dosed at its maximum tolerated dose due to limiting toxicities, 26, 27 makes it essential to reduce erlotinib dose in this scenario to as low as 25 mg once daily or to look for alternative treatment options. Gefitinib has a wider therapeutic range than erlotinib and the approved dose of gefitinib is only one-third of its maximum tolerated dose. 19, 28 Thus, although gefitinib concentrations in the presence of ritonavir were still high after reducing the standard dose by 50%, individual concentrations were considered to be within the therapeutic range, 28 and such a dose adjustment was considered appropriate.
At drug concentrations observed in clinical practice, CYP3A4 induction is more pronounced with efavirenz than with etravirine, [43] [44] [45] as reflected by the magnitude of their interactions. Our data showed a particularly marked decrease in erlotinib and gefitinib exposure when they were administered with efavirenz. Moreover, such interactions were not overcome even after doubling the erlotinib or gefitinib doses, making these combinations not recommended in clinical practice, especially if an alternative is available. Etravirine is a weaker inducer of CYP3A4 and its impact on erlotinib and gefitinib pharmacokinetics was low. In this case, we were able to identify potential dose adjustments to provide therapeutic concentrations of erlotinib and gefitinib in the presence of etravirine.
Gefitinib and erlotinib are substrates of drug transporters including ABCB1, BCRP and MRPs, 47 whose activity may be influenced by ritonavir, efavirenz or etravirine. 49, 50 However, both erlotinib and gefitinib are very potent inhibitors of these transporters and no additional inhibition was observed after co-incubation with other paradigm inhibitors such as cyclosporine A (an ABCG2 inhibitor), KO-143 (an ABCG2 inhibitor) and MK-571 (an inhibitor of ABCCs). 51 Despite the potential relevance of transporter activity in erlotinib and gefitinib disposition, we considered that there are still too many gaps in the knowledge of these processes to incorporate them into the current model. Although this might be considered as a limitation of the present study, our modelling approach proved to be robust. The simulated pharmacokinetics of erlotinib, gefitinib, darunavir/ritonavir, efavirenz and etravirine were in good accordance with previously described clinical data. Additionally, the inhibitory and inductive effects of the perpetrator drugs were validated by comparing the magnitude of simulated drug-drug interactions using probe drugs with that observed in clinical studies.
The absence of comparisons using other boosted PIs (e.g. atazanavir/ritonavir) may also be considered as a potential limitation of this study. However, as mentioned above, at clinical concentrations ritonavir causes almost complete inhibition of CYP3A4, with no additional inhibition by the addition of a second drug, 36 making our results potentially applicable to the scenario of atazanavir/ritonavir-containing cART.
Finally, we used a healthy patient population profile instead of HIV-infected or cancer patient profiles when performing the simulations. Pharmacokinetic differences between healthy volunteers and patients are well known due to different tissue composition, altered protein binding, etc. Consequently, discrepancies in drug exposure and also in the magnitude of drug-drug interactions between studies performed in healthy volunteers or in patients have been reported in some cases. This consideration makes a clinical validation of our results highly desirable.
In summary, we developed a PBPK model that predicted the pharmacokinetics of erlotinib, gefitinib, darunavir/ritonavir, efavirenz and etravirine, and their interactions. The clarification of the magnitude of drug-drug interactions between antiretrovirals and chemotherapeutic drugs is relevant since it may influence treatment outcome. The model presented here provides a rational platform both to optimize antineoplastic therapy in HIV patients receiving these key antiretrovirals as well as to inform the design for a clinical drug interaction study that may save time and resources, while the optimal dose is determined empirically. 
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